Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD | Zendy

Qi Wang | Zendy; Bing Xiao | Zendy; Shuqin Cui | Zendy; Hailong Song | Zendy; Yanjing Qian | Zendy; Lin Dong | Zendy; Haiting An | Zendy; Yanqiu Cui | Zendy; Wenjing Zhang | Zendy; Yi He | Zendy; Jianliang Zhang | Zendy; Jian Yang | Zendy; Feilong Zhang | Zendy; Guanzheng Hu | Zendy; Xiaoli Gong | Zendy; Zhen Yan | Zendy; Yan Zheng | Zendy; Xiaomin Wang | Zendy

Open Access

Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD

Author(s) -

Qi Wang,

Bing Xiao,

Shuqin Cui,

Hailong Song,

Yanjing Qian,

Lin Dong,

Haiting An,

Yanqiu Cui,

Wenjing Zhang,

Yi He,

Jianliang Zhang,

Jian Yang,

Feilong Zhang,

Guanzheng Hu,

Xiaoli Gong,

Zhen Yan,

Yan Zheng,

Xiaomin Wang

Publication year - 2014

Publication title -

disease models and mechanisms

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.327

H-Index - 83

eISSN - 1754-8411

pISSN - 1754-8403

DOI - 10.1242/dmm.018218

Subject(s) - triptolide , tripterygium wilfordii , genetically modified mouse , presenilin , oxidative stress , pharmacology , amyloid precursor protein , in vivo , transgene , neuroinflammation , inflammation , medicine , amyloid precursor protein secretase , alzheimer's disease , disease , biology , apoptosis , immunology , pathology , biochemistry , gene , alternative medicine , microbiology and biotechnology

The complex pathogenesis of Alzheimer's disease (AD) involves multiple contributing factors, including amyloid β (Aβ) peptide accumulation, inflammation and oxidative stress. Effective therapeutic strategies for AD are still urgently needed. Triptolide is the major active compound extracted from Tripterygium wilfordii Hook.f., a traditional Chinese medicinal herb that is commonly used to treat inflammatory diseases. The 5-month-old 5XFAD mice, which carry five familial AD mutations in the β-amyloid precursor protein (APP) and presenilin-1 (PS1) genes, were treated with triptolide for 8 weeks. We observed enhanced spatial learning performances, and attenuated Aβ production and deposition in the brain. Triptolide also inhibited the processing of amyloidogenic APP, as well as the expression of βAPP-cleaving enzyme-1 (BACE1) both in vivo and in vitro. In addition, triptolide exerted anti-inflammatory and anti-oxidative effects on the transgenic mouse brain. Triptolide therefore confers protection against the effects of AD in our mouse model and is emerging as a promising therapeutic candidate drug for AD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research